Cylex Expands Its Management Team

Cylex Inc. a privately held, venture-capital backed life science Company, announced today that Mr. Stephen Sproul has joined the Company as Director of Sales.

Columbia, Maryland (March 24, 2003) --

Cylex Inc. a privately held, venture-capital backed life science Company, announced today that Mr. Stephen Sproul has joined the Company as Director of Sales.

Mr. Sproul was most recently responsible for sales at Visible Genetics, Inc. (VGI), a Swanee, Georgia firm which manufactures and markets HIV-1 assays used in AIDS testing. Prior to VCI, Steve spent eighteen (18) years in Sales and Marketing management roles at multinational diagnostics firms, including Chiron Corporation, Bayer Diagnostics, and Sanofi Diagnostics.

Cylexs president and CEO, Judith A. Britz, Ph.D., said Steve is a great addition to our management Team. He brings a wealth of experience in selling diagnostic products to physicians and laboratories, exactly fitting our needs. His broad knowledge of the HIV market coincides with the current and future marketing objectives of Cylex".

Cylex is a life science Company that manufacturers and develops patented in vitro diagnostic products for the assessment of immunity. These products have utility for physicians treating life-threatening diseases or conditions who seek to optimize therapy through individualized management of patients immune system, thereby reducing side effects, improving clinical response and quality of life. ImmuKnowTM -- the Cylex® Immune Cell Function Assay is intended to be used as an adjunct to post-transplantation drug level monitoring along with other clinical indicators.

Cylexs patented platform technology will also provide an innovative approach for measuring immune activity in AIDS and cancer patients, and those with infectious diseases, autoimmune or other immune system disorders.

Additional information is available on the Companys website at www.cylex.net